Dr. Joanie Mayer Hope
Board Certified Gynecologic Oncologist, Dr. Joanie Mayer Hope is the founding partner of Alaska Women’s Cancer Care.
Based in Anchorage, Dr. Mayer Hope manages the surgical and chemotherapeutic aspects of women’s cancer treatment. Dr. Mayer Hope is the Director of Gyn Oncology at Providence Alaska Cancer Center and the Alaska Native Medical Center and also operates at Alaska Regional Hospital in Anchorage. By integrating care in these centers, she is able to offer women with gynecologic cancers the optimal treatment in the most appropriate and desired setting. Since moving to Alaska in 2010, she has become one of the highest volume robotic surgeons in the state.
Education
Dr. Mayer Hope is a graduate of Stanford University (B.A. in Economics, 1992), completed her Masters at Antioch University in Ohio (Intercultural Relations, 1997) and received her MD from State University of New York, Brooklyn in 2003 with honors. She completed her postgraduate training at New York University Medical Center including a 4-year residency in Obstetrics and Gynecology, where she served as administrative chief in 2007 followed by a 3-year fellowship in Gynecologic Oncology. She is board certified in both Obstetrics and Gynecology (2009) and Gynecologic Oncology (2011) through the American Board of Obstetrics and Gynecology.
Interests
Dr. Joanie Mayer Hope is passionate about the application of creativity to ending gynecologic cancers and fighting health disparities locally, nationally, and globally. Joanie is also a mother, athlete, and musician.
In 2012, she co-founded Let Every Woman Know-Alaska, a non-profit organization dedicated to preventing, facing and ending gynecologic cancers through creative statewide education, support, advocacy and arts programs unique to Alaska’s diverse communities www.leteverywomanknow.org.
From 2008 – 2018 Dr. Hope was the lead singer in the nationally recognized rock band, No Evidence of Disease (N.E.D.) dedicated raising gyn cancer awareness through music. N.E.D. was the subject of a feature length documentary released nationally in 2014 (www.nedthemovie.com).
In 2018 Joanie launched Any Mountain (www.anmountainsong.com), a wildly innovative project whose mission is to summit the toughest challenges in gynecologic cancer through creativity and research. In Spring of 2023, Dr. Hope lead a team of 20 survivors, providers, and caregivers to the Everest Base Camp in the name of a world without ovarian cancer. Together this Any Mountain team raised over half a million dollars and placed the first ovarian cancer survivor in history – Jess Wedel -- on the 29,032 foot summit of Mount Everest.
In 2023, as part of Any Mountain’s creative awareness campaign, Dr. Hope released 2 new music videos and 7 new original songs (www.anymountainmusic.com).
On the global front, Dr. Hope has joined forces with the gyn oncologist founder of Pothawira International (www.pothawira.org), Dr. Anne Alaniz, to help build a surgical center, launch a cancer program, and grow the global health presence in the Salima District of Malawi Africa where access to care is extremely limited.
Recent Media Coverage:
Publications
Eskander RN, Sill MS, Beffa L, Moore RG… Hope JM et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer, New England Journal of Medicine, 388: 2159-2170, June 8, 2023.
Hope JM, Whyte JS, What is the best management option for malignant bowel obstruction? Surgery. 50 Big Debates in Gynecologic Oncology, Cambridge Press, July 2023
HardestyM, HopeJM, KrivakT, ChenJ, WainszelbaumM, Gupta D, RichardsonD. OVARIO: a phase 2, single-arm, open-label study of maintenance therapy with niraparib + bevacizumab in patients with advanced ovarian cancer after response on frontline platinum-based chemotherapy. Annual Meeting European Society of Medical Oncology, 2018.
Hope JM, Chen J, Wainszelbaum M, Hardesty M,Gupta D. A Phase 2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Niraparib Combined with Bevacizumab as Maintenance Treatment in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Frontline Platinum-Based Chemotherapy with Bevacizumab (OVARIO). Annual Meeting American Society of Clinical Oncology, May 2018.
Hope JM, Nagarsheth NN. Music and Medicine, Music and Cancer Healing. Jones & Bartlett, November 2009; Chapter 10: 110, Chapter 11: 136.
Hope JM, Long K, Kudla M, Arslan A, Tsymbal T, Strok I, Timor Tritsch E. Three dimensional Power Doppler Angiography of Cyclical Ovarian Blood Flow, Journal of Ultrasound in Medicine, J Ultrasound Med. Aug 2009 28:1043-1052
Hope JM, Blank SV. Current status of maintenance therapy for advanced ovarian cancer. International Journal of Women’s Health August 2009; 1: 173-180. Published online 2010 August 9. PMCID: PMC2971701
Whyte JS, Gil OD, Hope JM, Pua T, Fishman DA. LPA- induced time dependent modulation of coflin phosphorylation promotes stimulation of migration and invasion in ovarian carcinoma cells. Gynecologic Oncology. Volume 112, Issue 1, January 2009, Pages 215-223.
Hope JM, Pothuri BP. The role of surgery in palliative gynecologic cancer cases. The Oncologist 2013; 18:73-79; first published on January 8, 2013; doi:10.1634/theoncologist. 2012-0328.
Hope JM, Long K, Pua T, Goldman N. Primary Presentation of Cervix Cancer in the Distal Femur: A Case Report and Literature Review. International Journal of Gynecological Cancer. August 2009 (In Submission)
Hope JM, Wang FQ, Whyte JS, Ariztia E, Abdalla W, Long K, Fishman DA. LPA Receptor 2 Mediates LPA-Induced Endometrial Cancer Invasion. Gynecologic Oncology. Jan 2009; 112(1):215-23.
Devine KM, Smicun Y, Hope JM, Fishman DA. S1P induced changes in Ovarian Cancer Cell Proteolysis, Invasion, and Attachment are Mediated by Gi and Rac, Gynecologic Oncology. Aug 2008;110(2):237-45.
Kudla M, Timor-Tritsch I, Hope JM, Monteagudo A, Popiolek D, Monda S, Lee CJ, Arslan AA. Spherical Tissue Sampling in 3-Dimensional Power Doppler Angiography, Journal of Ultrasound in Medicine, March 2008; 27: 425-433.
Gil OD, Lee C, Ariztia EV, Wang FQ, Smith PJ, Hope JM, Fishman DA. Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in a uPA dependent manner, Gynecologic Oncology, Jan 2008;108: 361-369
Hope JM, Petignat P, Blank SV, Bruchim I. Advancing Women’s Cancer Care: Report from the 37th Annual Meeting of the Society of Gynecologic Oncologists, Gynakologisch-Geburtshilfliche Rundschau. 2006; 46(4):214-7
Hope JM, Lugassy D, Meyer R, Jeanty F, Myers S, Jones S, Bradley J, Mitchell R, Cramer E. Bringing Multicultural & Interdisciplinary Team-Building to Healthcare Education: The Downstate Team Building Initiative. Academic Medicine. 2005; 80(1): 74-83.
